Download PDF
Semin Respir Crit Care Med 2019; 40(02): 227-234
DOI: 10.1055/s-0039-1685537
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pulmonary Complications of Systemic Lupus Erythematosus

Jennifer R. Hannah
1   Department of Rheumatology, King's College London, London, United Kingdom
,
David P. D'Cruz
2   Louise Coote Lupus Unit, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
28 May 2019 (online)

   Permissions and Reprints

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by the production of pathogenic autoantibodies and immune complexes and is responsible for significant morbidity and mortality through a wide range of clinical manifestations which can affect almost any organ. Pulmonary involvement is prevalent and seen in 50 to 70% of SLE patients and may even be the presenting feature in 4 to 5% of patients. By 10 years postdiagnosis, 12% will have accumulated an element of permanent lung damage. Pulmonary complications are broad and include pleural disease, interstitial lung disease (ILD), vasculitis, pulmonary embolism, pulmonary hypertension, large airway disease, shrinking lung syndrome, and infection. Conditions can range mostly from asymptomatic, for example, in mild cases of pleural effusion or obstructive airway disease, to life-threatening disease, for example, in acute lupus pneumonitis or diffuse alveolar hemorrhage. ILD and pulmonary hypertension are both frequently seen in other autoimmune rheumatic diseases such as systemic sclerosis; however, in SLE, they tend to be milder and have a comparatively favorable prognosis. Although collectively pulmonary involvement in SLE is common, the heterogeneity of SLE and rareness of individual complications make clinical trials difficult and treatment is usually based on case series reports and anecdotal experience with various immunosuppressive agents. Some of these immunosuppressive agents such as azathioprine, methotrexate, and cyclophosphamide have also been linked with drug-induced lung injury.

Keywords

systemic lupus erythematosus - pulmonary disease - complications - interstitial lung disease - pleural disease
 

  • References

  • 1 Vitali C, Bencivelli W, Isenberg DA. , et al; European Consensus Study Group for Disease Activity in SLE. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. Clin Exp Rheumatol 1992; 10 (05) 527-539
    PubMedGoogle Scholar
  • 2 Petri M, Orbai AM, Alarcón GS. , et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64 (08) 2677-2686
    CrossrefPubMedGoogle Scholar
  • 3 Keane MP, Lynch III JP. Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax 2000; 55 (02) 159-166
    CrossrefPubMedGoogle Scholar
  • 4 Bertoli AM, Vila LM, Apte M. , et al; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus 2007; 16 (06) 410-417
    CrossrefPubMedGoogle Scholar
  • 5 Torre O, Harari S. Pleural and pulmonary involvement in systemic lupus erythematosus. Presse Med 2011; 40 (1 Pt 2): e19-e29
    PubMedGoogle Scholar
  • 6 Hooper C, Lee YC, Maskell N. ; BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 (Suppl. 02) ii4-ii17
    PubMedGoogle Scholar
  • 7 Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus: computer analysis of 520 cases. JAMA 1964; 190 (02) 104-111
    PubMedGoogle Scholar
  • 8 Wang D-Y. Diagnosis and management of lupus pleuritis. Curr Opin Pulm Med 2002; 8 (04) 312-316
    CrossrefPubMedGoogle Scholar
  • 9 Good Jr JT, King TE, Antony VB, Sahn SA. Lupus pleuritis. Clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibodies. Chest 1983; 84 (06) 714-718
    CrossrefPubMedGoogle Scholar
  • 10 Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979; 119 (03) 471-503
    PubMedGoogle Scholar
  • 11 Porcel JM, Ordi-Ros J, Esquerda A. , et al. Antinuclear antibody testing in pleural fluid for the diagnosis of lupus pleuritis. Lupus 2007; 16 (01) 25-27
    CrossrefPubMedGoogle Scholar
  • 12 Blomgren SE, Condemi JJ, Vaughan JH. Procainamide-induced lupus erythematosus. Clinical and laboratory observations. Am J Med 1972; 52 (03) 338-348
    CrossrefPubMedGoogle Scholar
  • 13 McKnight KM, Adair NE, Agudelo CA. Successful use of tetracycline pleurodesis to treat massive pleural effusion secondary to systemic lupus erythematosus. Arthritis Rheum 1991; 34 (11) 1483-1484
    PubMedGoogle Scholar
  • 14 Mittoo S, Fell CD. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med 2014; 35 (02) 249-254
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Weinrib L, Sharma OP, Quismorio Jr FP. A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin Arthritis Rheum 1990; 20 (01) 48-56
    CrossrefPubMedGoogle Scholar
  • 16 Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol 1996; 166 (02) 301-307
    CrossrefPubMedGoogle Scholar
  • 17 Andonopoulos AP, Constantopoulos SH, Galanopoulou V, Drosos AA, Acritidis NC, Moutsopoulos HM. Pulmonary function of nonsmoking patients with systemic lupus erythematosus. Chest 1988; 94 (02) 312-315
    CrossrefPubMedGoogle Scholar
  • 18 Haupt HM, Moore GW, Hutchins GM. The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med 1981; 71 (05) 791-798
    CrossrefPubMedGoogle Scholar
  • 19 Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ 2016; 352: h6819
    CrossrefPubMedGoogle Scholar
  • 20 ter Borg EJ, Groen H, Horst G, Limburg PC, Wouda AA, Kallenberg CG. Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. Semin Arthritis Rheum 1990; 20 (03) 164-173
    CrossrefPubMedGoogle Scholar
  • 21 Hedgpeth MT, Boulware DW. Interstitial pneumonitis in antinuclear antibody-negative systemic lupus erythematosus: a new clinical manifestation and possible association with anti-Ro (SS-A) antibodies. Arthritis Rheum 1988; 31 (04) 545-548
    CrossrefPubMedGoogle Scholar
  • 22 Frankel SK, Brown KK. Collagen vascular diseases of the lung. Clin Pulm Med 2006; 13 (01) 25-36
    CrossrefPubMedGoogle Scholar
  • 23 Matthay RA, Schwarz MI, Petty TL. , et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 1975; 54 (05) 397-409
    PubMedGoogle Scholar
  • 24 Quismorio Jr FP. Pulmonary manifestations of systemic lupus erythematosus. In: Dubois' Lupus Erythematosus, 5th ed. Baltimore, USA: Williams & Wilkins; 1997: 673-692
    Google Scholar
  • 25 Wan SA, Teh CL, Jobli AT. Lupus pneumonitis as the initial presentation of systemic lupus erythematosus: case series from a single institution. Lupus 2016; 25 (13) 1485-1490
    CrossrefPubMedGoogle Scholar
  • 26 Belmont HM, Buyon J, Giorno R, Abramson S. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus: the Shwartzman phenomenon revisited. Arthritis Rheum 1994; 37: 376-383
    CrossrefPubMedGoogle Scholar
  • 27 Belmont HM, Buyon J, Giorno R, Abramson S. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum 1994; 37 (03) 376-383
    CrossrefPubMedGoogle Scholar
  • 28 Dhala A. Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol 2012; 2012: 854941
    PubMedGoogle Scholar
  • 29 Lian F, Chen D, Wang Y. , et al. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int 2012; 32 (06) 1727-1731
    CrossrefPubMedGoogle Scholar
  • 30 Galiè N, Hoeper MM, Humbert M. , et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30 (20) 2493-2537
    CrossrefPubMedGoogle Scholar
  • 31 Chung S-M, Lee C-K, Lee EY, Yoo B, Lee S-D, Moon H-B. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 2006; 25 (06) 866-872
    CrossrefPubMedGoogle Scholar
  • 32 Hachulla E, Jais X, Cinquetti G. , et al; French Collaborators Recruiting Members(*). Pulmonary arterial hypertension associated with systemic lupus erythematosus: results from the French pulmonary hypertension registry. Chest 2018; 153 (01) 143-151
    CrossrefPubMedGoogle Scholar
  • 33 Condliffe R, Kiely DG, Peacock AJ. , et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179 (02) 151-157
    CrossrefPubMedGoogle Scholar
  • 34 Kommireddy S, Bhyravavajhala S, Kurimeti K. , et al. Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study. Rheumatology (Oxford) 2015; 54 (09) 1673-1679
    CrossrefPubMedGoogle Scholar
  • 35 Andrade C, Mendonça T, Farinha F. , et al. Alveolar hemorrhage in systemic lupus erythematosus: a cohort review. Lupus 2016; 25 (01) 75-80
    CrossrefPubMedGoogle Scholar
  • 36 Churg A, Franklin W, Chan KL, Kopp E, Carrington CB. Pulmonary hemorrhage and immune-complex deposition in the lung. Complications in a patient with systemic lupus erythematosus. Arch Pathol Lab Med 1980; 104 (07) 388-391
    PubMedGoogle Scholar
  • 37 Koh W-H, Thumboo J, Boey M-L. Pulmonary haemorrhage in oriental patients with systemic lupus erythematosus. Lupus 1997; 6 (09) 713-716
    CrossrefPubMedGoogle Scholar
  • 38 Ewan PW, Jones HA, Rhodes CG, Hughes JM. Detection of intrapulmonary hemorrhage with carbon monoxide uptake. Application in Goodpasture's syndrome. N Engl J Med 1976; 295 (25) 1391-1396
    CrossrefPubMedGoogle Scholar
  • 39 Hughson MD, He Z, Henegar J, McMurray R. Alveolar hemorrhage and renal microangiopathy in systemic lupus erythematosus. Arch Pathol Lab Med 2001; 125 (04) 475-483
    CrossrefPubMedGoogle Scholar
  • 40 Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997; 76 (03) 192-202
    PubMedGoogle Scholar
  • 41 Lee JG, Joo KW, Chung WK. , et al. Diffuse alveolar hemorrhage in lupus nephritis. Clin Nephrol 2001; 55 (04) 282-288
    PubMedGoogle Scholar
  • 42 Walsh M, Merkel PA, Jayne D. The effects of plasma exchange and reduced-dose glucocorticoids during remission-induction for treatment of severe ANCA-associated vasculitis. Arthritis Rheum 2018; 70 (Suppl. 10) 2788
    PubMedGoogle Scholar
  • 43 Schwab EP, Schumacher Jr HR, Freundlich B, Callegari PE. Pulmonary alveolar hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum 1993; 23 (01) 8-15
    CrossrefPubMedGoogle Scholar
  • 44 Martínez-Martínez MU, Abud-Mendoza C. Predictors of mortality in diffuse alveolar haemorrhage associated with systemic lupus erythematosus. Lupus 2011; 20 (06) 568-574
    CrossrefPubMedGoogle Scholar
  • 45 Specks U. Diffuse alveolar hemorrhage syndromes. Curr Opin Rheumatol 2001; 13 (01) 12-17
    CrossrefPubMedGoogle Scholar
  • 46 Abramson SB, Dobro J, Eberle MA. , et al. Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med 1991; 114 (11) 941-947
    CrossrefPubMedGoogle Scholar
  • 47 Pego-Reigosa JM, Medeiros DA, Isenberg DA. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol 2009; 23 (04) 469-480
    CrossrefPubMedGoogle Scholar
  • 48 Gladman DD, Urowitz MB. Venous syndromes and pulmonary embolism in systemic lupus erythematosus. Ann Rheum Dis 1980; 39 (04) 340-343
    CrossrefPubMedGoogle Scholar
  • 49 Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112 (09) 682-698
    CrossrefPubMedGoogle Scholar
  • 50 Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006; 295 (09) 1050-1057
    CrossrefPubMedGoogle Scholar
  • 51 Gordon C, Amissah-Arthur M-B, Gayed M. , et al; British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 2018; 57 (01) e1-e45
    CrossrefPubMedGoogle Scholar
  • 52 Groen H, ter Borg EJ, Postma DS, Wouda AA, van der Mark TW, Kallenberg CG. Pulmonary function in systemic lupus erythematosus is related to distinct clinical, serologic, and nailfold capillary patterns. Am J Med 1992; 93 (06) 619-627
    CrossrefPubMedGoogle Scholar
  • 53 Kinney WW, Angelillo VA. Bronchiolitis in systemic lupus erythematosus. Chest 1982; 82 (05) 646-649
    CrossrefPubMedGoogle Scholar
  • 54 Godeau B, Cormier C, Menkes CJ. Bronchiolitis obliterans in systemic lupus erythematosus: beneficial effect of intravenous cyclophosphamide. Ann Rheum Dis 1991; 50 (12) 956-958
    CrossrefPubMedGoogle Scholar
  • 55 Gammon RB, Bridges TA, al-Nezir H, Alexander CB, Kennedy Jr JI. Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematosus. Chest 1992; 102 (04) 1171-1174
    CrossrefPubMedGoogle Scholar
  • 56 Hoffbrand BI, Beck ER. “Unexplained” dyspnoea and shrinking lungs in systemic lupus erythematosus. BMJ 1965; 1 (5445): 1273-1277
    CrossrefPubMedGoogle Scholar
  • 57 Duron L, Cohen-Aubart F, Diot E. , et al. Shrinking lung syndrome associated with systemic lupus erythematosus: a multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. Autoimmun Rev 2016; 15 (10) 994-1000
    CrossrefPubMedGoogle Scholar
  • 58 Karim MY, Miranda LC, Tench CM. , et al. Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus. Semin Arthritis Rheum 2002; 31 (05) 289-298
    CrossrefPubMedGoogle Scholar
  • 59 Muñoz-Rodríguez FJ, Font J, Badia JR. , et al. Shrinking lungs syndrome in systemic lupus erythematosus: improvement with inhaled beta-agonist therapy. Lupus 1997; 6 (04) 412-414
    CrossrefPubMedGoogle Scholar
  • 60 Martens J, Demedts M, Vanmeenen MT, Dequeker J. Respiratory muscle dysfunction in systemic lupus erythematosus. Chest 1983; 84 (02) 170-175
    CrossrefPubMedGoogle Scholar
  • 61 Laroche CM, Mulvey DA, Hawkins PN. , et al. Diaphragm strength in the shrinking lung syndrome of systemic lupus erythematosus. Q J Med 1989; 71 (265) 429-439
    PubMedGoogle Scholar
  • 62 Toya SP, Tzelepis GE. Association of the shrinking lung syndrome in systemic lupus erythematosus with pleurisy: a systematic review. Semin Arthritis Rheum 2009; 39 (01) 30-37
    CrossrefPubMedGoogle Scholar
  • 63 Van Veen S, Peeters AJ, Sterk PJ, Breedveld FC. The “shrinking lung syndrome” in SLE, treatment with theophylline. Clin Rheumatol 1993; 12 (04) 462-465
    CrossrefPubMedGoogle Scholar
  • 64 Thompson PJ, Dhillon DP, Ledingham J, Turner-Warwick M. Shrinking lungs, diaphragmatic dysfunction, and systemic lupus erythematosus. Am Rev Respir Dis 1985; 132 (04) 926-928
    PubMedGoogle Scholar
  • 65 Klemperer P, Pollack AD, Baehr G. Pathology of disseminated lupus erythematosus. Arch Pathol Lab Med 1941; 32: 569-579
    PubMedGoogle Scholar
  • 66 Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003; 15 (05) 528-534
    CrossrefPubMedGoogle Scholar
  • 67 Garred P, Madsen HO, Halberg P. , et al. Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum 1999; 42 (10) 2145-2152
    CrossrefPubMedGoogle Scholar
  • 68 Piliero P, Furie R. Functional asplenia in systemic lupus erythematosus. Semin Arthritis Rheum 1990; 20 (03) 185-189
    CrossrefPubMedGoogle Scholar
  • 69 Neilan BA, Berney SN. Hyposplenism in systemic lupus erythematosus. J Rheumatol 1983; 10 (02) 332-334
    PubMedGoogle Scholar
  • 70 Zonana-Nacach A, Camargo-Coronel A, Yañez P, Sánchez L, Jimenez-Balderas FJ, Fraga A. Infections in outpatients with systemic lupus erythematosus: a prospective study. Lupus 2001; 10 (07) 505-510
    CrossrefPubMedGoogle Scholar
  • 71 Duffy KN, Duffy CM, Gladman DD. Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol 1991; 18 (08) 1180-1184
    PubMedGoogle Scholar
  • 72 Narata R, Wangkaew S, Kasitanon N, Louthrenoo W. Community-acquired pneumonia in Thai patients with systemic lupus erythematosus. Southeast Asian J Trop Med Public Health 2007; 38 (03) 528-536
    PubMedGoogle Scholar
  • 73 Bin J, Bernatsky S, Gordon C. , et al. Lung cancer in systemic lupus erythematosus. Lung Cancer 2007; 56 (03) 303-306
    CrossrefPubMedGoogle Scholar
  • 74 Bernatsky S, Boivin JF, Joseph L. , et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54 (08) 2550-2557
    CrossrefPubMedGoogle Scholar
  • 75 Artinian V, Kvale PA. Cancer and interstitial lung disease. Curr Opin Pulm Med 2004; 10 (05) 425-434
    CrossrefPubMedGoogle Scholar
  • 76 Schwaiblmair M, Behr W, Haeckel T, Märkl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J 2012; 6: 63-74
    CrossrefPubMedGoogle Scholar
  • 77 Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000; 20 (05) 1245-1259
    CrossrefPubMedGoogle Scholar
  • 78 Ellis SJ, Cleverley JR, Müller NL. Drug-induced lung disease: high-resolution CT findings. AJR Am J Roentgenol 2000; 175 (04) 1019-1024
    CrossrefPubMedGoogle Scholar
  • 79 Ruano CA, Lucas RN, Leal CI. , et al. Thoracic manifestations of connective tissue diseases. Curr Probl Diagn Radiol 2015; 44 (01) 47-59
    CrossrefPubMedGoogle Scholar